Alopecia is defined as the loss of hair of any type and origin. It is the reason for up to 8% of the dermatological consultations. The most common form is androgenetic alopecia and affects many men and some women.
In 5% of men it begins before the age of 20 but it is more commonly found in adults. Towards the age of 60, baldness manifests itself in 40% of men. In women androgenetic alopecia is less frequent and usually does not occur before menopause.
This pharmacy's team for their rapid results has selected the following treatments..
(28 tablets):
Their active ingredient finasterid acts as a blocking agent against an enzyme, which occurs during the regulation of the hair folicle. It is used in the earlystages of the androgenetic alopecia in men.
(minoxydile 2-5% in flasks of 60 ml):
This is a solution for cutaneous application in cases of androgenetic alopecia.
(18 amp):
Ampoules of aminexil. It has been demonstrated that with aminexil there is an increase of 8% in hair growth when taking the placebo. This is available in two types:
· Dercos-Man:- This is a 1.5% solution of Aminexil, that favours hair growth, Triclosan and Piroctona Olamina for irritation of the roots and Vichy Thermal water wich is a soothing anti-irritatant.
· Dercos-Woman:- This is a 1.5% of Aminexil and vitamins PP/B5/B6 that favours natural hair growth.




cresci na

Labo Cosprophar laboratories in 1991 created Crescina, a complex of amino acids, Cysteine and Lysine, blended into an anti-hair loss preparation with vasodilator action, also able to encourage hair regrowth by stimulating hair bulbs that are still active.
In 1998 the discovery acquired a solid dimension when the combination of amino acids, Cysteine and Lysine, was added to a Glycoprotein able to stimulate cell metabolism in bulbs that are still active, increasing the process of protein synthesis, that is to say the production of keratin that leads to hair growth.
In 1998 Crescina, an outstanding avant-garde product, was registered with a Swiss patent: this was not just another hair loss preparation like so many others, but a treatment capable of reactivating the physiological growth of hair in areas affected by thinning, formulated in different dosages to deal with various levels of thinning, applying the scientifically acquired classification of the phenomenon, which uses the Hamilton scale for men and the Ludwig scale for women.
Crescina is a product available in vials for topical cosmetic use. It will have no effect on totally atrophied hair follicles .


Pantogar acts over the blood stream and improves the own metabolism of the hair. Pantogar is an oral vitamin preparation to ensure healthy and full hair.


  • General conditions: the information provided from Roser Miro Pharmacy's Web is directed to complement, not to substitute the existent relationship between a patient and his or her doctor.
  • Privacy and confidentiality policy: Whatever communication conveyed through the Web of Roser Miró Pharmacy is strictly confidential; although the electronic addresses and their content can be kept, your information will not be shared with any external source.
  • Legislation: This Web is managed by Roser Miró pharmacy, legally established in Escaldes, Principality of Andorra. The terms and conditions of usage of this Web are protected under the laws that rule in Andorra. Equally all its products and medicines have been authorized by the Health and Social Health Ministry of the Government of Andorra.
  • Links: The Web of the pharmacy contains links to other Webs, normally those of the labs which manufacture the different products. These links are offered as services and information to provide the maximum information about the products, medicines and treatments, relative to health and well-being.
  • Financing and advertising: This Web neither receives nor has any financing from advertising.
  • The information of this web has been produced by the pharmacists of Roser Miró Pharmacy's team, starting from approvals and subsequent information from the European medicines agency and the USA Food and Drug administration and from the manufacturing pharmaceutical laboratories.


Last modified: 7 September 2007